Multiple endocrine neoplasia type 2 screening: Difference between revisions
Line 11: | Line 11: | ||
*The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. | *The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. | ||
*The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]].<ref name="Yip2003">{{cite journal|last1=Yip|first1=Linwah|title=Multiple Endocrine Neoplasia Type 2|journal=Archives of Surgery|volume=138|issue=4|year=2003|pages=409|issn=0004-0010|doi=10.1001/archsurg.138.4.409}}</ref> | *The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]].<ref name="Yip2003">{{cite journal|last1=Yip|first1=Linwah|title=Multiple Endocrine Neoplasia Type 2|journal=Archives of Surgery|volume=138|issue=4|year=2003|pages=409|issn=0004-0010|doi=10.1001/archsurg.138.4.409}}</ref> | ||
* Screening for multiple endocrine neoplasia type 2 include the following tests. | * Screening for multiple endocrine neoplasia type 2 include the following tests.<ref>Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015</ref> | ||
{| | {| | ||
|- | |- | ||
Line 20: | Line 21: | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align="left" | '''The DNA-based testing of the c-RET gene''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align="left" | '''The DNA-based testing of the c-RET gene''' | ||
|- | |- | ||
| rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Children with c-[[RET gene|RET]] codon 609, 768, 790, 791, 804 and 891 [[mutations]] are more prone to less aggressive and slowly growing [[medullary thyroid cancer]] and a periodic [[pentagastrin]]-stimulated test with [[thyroidectomy]], at the first abnormal test result, has been recommended. | | rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Children with c-[[RET gene|RET]] codon 609, 768, 790, 791, 804 and 891 [[mutations]] are more prone to less aggressive and slowly growing [[medullary thyroid cancer]] and a periodic [[pentagastrin]]-stimulated test with [[thyroidectomy]], at the first abnormal test result, has been recommended. | ||
|- | |- | ||
| rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-[[RET gene|RET]] codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated [[Urinary system|urinary]] and free plasma [[metanephrine]]s and [[catecholamine]]s. | | rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-[[RET gene|RET]] codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated [[Urinary system|urinary]] and free plasma [[metanephrine]]s and [[catecholamine]]s. | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" | | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|} | |} | ||
* [[Screening]] of the [[pregnant]] woman with an increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the [[RET gene|''RET'' gene]] of the offspring. | * [[Screening]] of the [[pregnant]] woman with an increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the [[RET gene|''RET'' gene]] of the offspring. |
Revision as of 13:34, 24 June 2019
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2.
- The DNA-based testing of the c-RET gene can be easily performed on a blood sample at any age.
- The DNA-based testing of the c-RET gene offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor.
- The DNA-based testing of the c-RET gene test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.[1]
- Screening for multiple endocrine neoplasia type 2 include the following tests.[2]
References
|